Education
About Us
Working with TipRanks
Follow Us
Sino Biopharmaceutical (HK:1177)
:1177
1177 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$2.29 - HK$4.25
Previous CloseN/A
Volume63.93M
Average Volume (3M)109.05M
Market Cap
HK$72.70B
Enterprise ValueHK$55.37B
Total Cash (Recent Filing)¥1.76B
Total Debt (Recent Filing)¥198.43M
Price to Earnings (P/E)36.7
Beta1.17
Next Earnings
Aug 28, 2025EPS Estimate
0.09Next Dividend Ex-Date
Jun 16, 2025Dividend Yield1.69%
Share Statistics
EPS (TTM)0.10
Shares Outstanding18,769,717,000
10 Day Avg. Volume125,875,975
30 Day Avg. Volume109,046,179
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)N/A
Price to Sales (P/S)2.59
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.27Price Target Upside9.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Sino Biopharmaceutical News
PremiumCompany Announcements
Sino Biopharmaceutical’s TQB6411 Clinical Trial Application Accepted
PremiumCompany Announcements
Sino Biopharmaceutical Reports Strong 2024 Financial Results
PremiumCompany Announcements
Sino Biopharmaceutical Announces Final Dividend for 2024
PremiumCompany Announcements
Sino Biopharm Reports Strong Financial Growth in 2024
PremiumCompany Announcements
Sino Biopharmaceutical’s Rovadicitinib Shows Promise in cGVHD Treatment
PremiumCompany Announcements
Sino Biopharmaceutical Schedules Board Meeting to Approve Annual Results---
Options Prices
Currently, No data available
---
Ownership Overview
15.48% Insiders
2.56%
Mutual Funds
<0.01% Other Institutional Investors
76.76% Public Companies and
Individual Investors
1177 FAQ
What was Sino Biopharmaceutical’s price range in the past 12 months?
Sino Biopharmaceutical lowest stock price was HK$2.29 and its highest was HK$4.25 in the past 12 months.
What is Sino Biopharmaceutical’s market cap?
Sino Biopharmaceutical’s market cap is HK$72.70B.
When is Sino Biopharmaceutical’s upcoming earnings report date?
Sino Biopharmaceutical’s upcoming earnings report date is Aug 28, 2025 which is in 142 days.
How were Sino Biopharmaceutical’s earnings last quarter?
Sino Biopharmaceutical released its earnings results on Mar 20, 2025. The company reported HK$0.032 earnings per share for the quarter, missing the consensus estimate of HK$0.085 by -HK$0.053.
Is Sino Biopharmaceutical overvalued?
According to Wall Street analysts Sino Biopharmaceutical’s price is currently Undervalued.
Does Sino Biopharmaceutical pay dividends?
Sino Biopharmaceutical pays a Annually dividend of HK$0.039 which represents an annual dividend yield of 1.69%. See more information on Sino Biopharmaceutical dividends here
What is Sino Biopharmaceutical’s EPS estimate?
Sino Biopharmaceutical’s EPS estimate is 0.09.
How many shares outstanding does Sino Biopharmaceutical have?
Sino Biopharmaceutical has 18,769,717,000 shares outstanding.
What happened to Sino Biopharmaceutical’s price movement after its last earnings report?
Sino Biopharmaceutical reported an EPS of HK$0.032 in its last earnings report, missing expectations of HK$0.085. Following the earnings report the stock price went up 1.648%.
Which hedge fund is a major shareholder of Sino Biopharmaceutical?
Currently, no hedge funds are holding shares in HK:1177
---
Sino Biopharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$4.27 (9.87% Upside)
HK$4.27 (9.87% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.76%
12-Months-Change
Fundamentals
Return on Equity
6.14%
Trailing 12-Months
Asset Growth
-0.08%
Trailing 12-Months
Company Description
Sino Biopharmaceutical
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
---
1177 Stock 12 Month Forecast
Average Price Target
HK$4.27
▲(9.87% Upside)
Technical Analysis
Ping An Insurance Company of China
―
CSPC Pharmaceutical Group
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Huazhu Group Ltd
―
Best Analysts Covering 1177
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-9.89%
reiterated a buy rating 18 days ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -9.89% per trade.
---